NCT02430714 is a clinical trial of Lenvatinib in Thyroid Neoplasms, sponsored by Eisai Co., Ltd..

Who is sponsoring NCT02430714?

NCT02430714 is sponsored by Eisai Co., Ltd..

What drugs are being tested in NCT02430714?

Interventions in NCT02430714: Lenvatinib.

What condition does NCT02430714 study?

NCT02430714 studies Thyroid Neoplasms.

Is NCT02430714 still recruiting?

NCT02430714 is currently completed. Last updated 9 January 2020.

Last reviewed 2020-01-09 · How we verify

NCT02430714

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)

Completed Last updated 9 January 2020

What this trial tests

trial testing Lenvatinib in Thyroid Neoplasms in 629 participants. Completed in 6 November 2016.

Timeline

20 May 2015

Primary endpoint
6 November 2016

6 November 2016

Quick facts

Lead sponsor	Eisai Co., Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	629
Start date	20 May 2015
Primary completion	6 November 2016
Estimated completion	6 November 2016
Sites	2 locations across Japan

Drugs / interventions tested

Lenvatinib (LENVATINIB) — full drug profile →

Conditions studied

Thyroid Neoplasms — all drugs for Thyroid Neoplasms →

Sponsor

Eisai Co., Ltd. — full company profile →

Who can join

Eligibility, any sex, with Thyroid Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a post-marketing surveillance of lenvatinib in participants with unresectable thyroid cancer. The objectives of this study are to capture unknown adverse reactions, incidences of adverse drug reaction, efficacy, factors considered to have effect to safety and effectiveness, and incidences of hypertension, hemorrhagic events and thromboembolic event, and liver disorder.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors.
Ancker OV, Wehland M, Bauer J, Infanger M, et al · · 2017 · cited 48× · PMID 28335429 · DOI 10.3390/ijms18030625
Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
Takahashi S, Tahara M, Ito K, Tori M, et al · · 2020 · cited 40× · PMID 32676927 · DOI 10.1007/s12325-020-01433-8
Optimal use of lenvatinib in the treatment of advanced thyroid cancer.
Takahashi S, Kiyota N, Tahara M. · · 2017 · cited 20× · PMID 31093354 · DOI 10.1186/s41199-017-0026-0

Verify or expand the search:

Other trials of Lenvatinib

Trials testing the same drug.

NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting
NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting
NCT07493668 — Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy · Phase 2 · not yet recruiting

Other recruiting trials for Thyroid Neoplasms

Currently open trials in the same condition.

NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
NCT07447089 — EMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study · NA · recruiting
NCT07010380 — Dual-Channel Near-Infrared Autofluorescence Imaging and AI Analysis to Locate Parathyroid Glands (PTFinder) · recruiting
NCT07434206 — Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors · Phase 2, PHASE3 · active not recruiting
NCT06398795 — Dual-port Trans-subclavian Thyroid Endoscopic Surgery · NA · recruiting

Other Eisai Co., Ltd. trials

Trials by the same sponsor.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G · recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02430714 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 9 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02430714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing